<DOC>
	<DOCNO>NCT00686868</DOCNO>
	<brief_summary>This study examine safety tolerability , PK PD subcutaneously administer GSK1841157 patient RA stable dose Methotrexate . The study comprise single dose escalation/de-escalation phase investigate minimal efficacious dose base PD marker acceptable safety profile .</brief_summary>
	<brief_title>Study Evaluate SC Route Administration Ofatumumab RA Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Key Male female age ≥ 18 year A diagnosis rheumatoid arthritis accord American College Rheumatology ( ACR1987 classification ) least six month prior screen Subjects must treat MTX , 7.525 mg/week , least 12 week prior Visit 2 , last 4 week prior Day 2 stable dosage Patient must willing receive folic acid ≥5mg/wk 4 week prior baseline administer accord locally accept practice Body mass index ( BMI ) &lt; 35kg/m2 ( inclusive ) Capable give write informed consent , include compliance requirement restriction list consent form Key Subjects history rheumatic autoimmune disease RA ( except secondary Sjögren 's syndrome ) , significant systemic involvement secondary RA ( vasculitis , pulmonary fibrosis Felty 's syndrome ) Previous exposure biologic cell deplete antirheumatic therapy , include investigational compound ( e.g . antiCD11a , antiCD19 , antiCD20 , antiCD22 , antiBLyS/BAFF , antiCD3 , antiCD4 , antiCD5 , antiCD52 ) Exposure etanercept &lt; 4 week , infliximab adalimumab &lt; 8 week , abatacept anakinra &lt; 12 week prior visit 2 Received follow treatment within 4 week prior Visit 2 : Anticancer therapy ( e.g . alkylating agent , antimetabolite , purine analogue , monoclonal antibody ) Glucocorticoid unless give dos equivalent ≤ 10 mg prednisolone /day Intraarticular , i.m . IV corticosteroid Live/attenuated vaccination Cyclosporine Azathioprine Penicillamine Sulfasalazine Bucillamine Hydroxychloroquine Chloroquine Exposure leflunomide within 12 week prior visit 2 unless subject complete peroral cholestyramine treatment Exposure gold therapy ≤ 12 week prior Visit 2 Exposure IV immunogammaglobulins ≤ 24 week prior Visit 2 Past current malignant melanoma Chronic ongoing active infectious disease require systemic treatment , limited , renal infection , chest infection bronchiectasis , tuberculosis active hepatitis B C History significant cerebrovascular disease Positive plasma / white cell JC Virus ( JCV ) PCR ( either compartment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>GSK1841157 ;</keyword>
	<keyword>rheumatoid arthritis ,</keyword>
	<keyword>B-cell depletion</keyword>
	<keyword>anti-CD20 monoclonal antibody ,</keyword>
</DOC>